1453211-61-4

Basic information

• Product Name: 2-chloro-5-[(2,6-difluoro-3,5-dimethoxyphenyl)methoxy]pyrimidine
• Synonyms: 2-chloro-5-[(2,6-difluoro-3,5-dimethoxyphenyl)methoxy]pyrimidine
• CAS NO: 1453211-61-4
• Molecular Weight: 316.692
• Mol File: 1453211-61-4.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 2-chloro-5-[(2,6-difluoro-3,5-dimethoxyphenyl)methoxy]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-5-[(2,6-difluoro-3,5-dimethoxyphenyl)methoxy]pyrimidine(1453211-61-4)
• EPA Substance Registry System: 2-chloro-5-[(2,6-difluoro-3,5-dimethoxyphenyl)methoxy]pyrimidine(1453211-61-4)

Safety Data

• Hazardous Substances Data: 1453211-61-4(Hazardous Substances Data)

Upstream product

• 651734-56-4 2,6-difluoro-3,5-dimethoxybenzoic acid 
• 7311-34-4 3,5-dimethoxybenzaldehdye 
• 1890954-24-1 2,6-difluoro-3,5-dimethoxybenzene(meth)aldehyde 
• 4983-28-2 2-chloropyrimidine-5-ol 
• 1208434-90-5 (2,6-difluoro-3,5-dimethoxyphenyl)methanol 
• 651734-55-3 methyl 2,6-difluoro-3,5-dimethoxybenzoate 
• 2150-37-0 methyl 3,5-dimethoxybenzoate 
• 1453211-60-3 (2,6-difluoro-3,5-dimethoxyphenyl)methyl methanesulfonate 

Downstream Products

• 1453211-13-6 2-[4-({5-[(2,6-difluoro-3,5-dimethoxybenzyl)oxy]pyrimidin-2-yl}amino)phenoxy]-2-methylpropionic acid 
• 1453211-32-9 N-[1-(azetidin-3-yl)-1H-pyrazol-4-yl]-5-[(2,6-difluoro-3,5-dimethoxybenzyl)oxy]pyrimidin-2-amine 

Relevant articles and documents

COMPOUNDS FOR INHIBITING FGFR4

Provided herein are compounds which inhibit FGFR4, compositions thereof, methods of their preparation, and methods for treating disorders mediated by FGFR4 such as cancer.

Discovery and optimization of selective FGFR4 inhibitors via scaffold hopping

Introduction of a Michael acceptor on a flexible scaffold derived from pan-FGFR inhibitors has successfully yielded a novel series of highly potent FGFR4 inhibitors with selectivity over FGFR1. Due to reduced lipophilicity and aromatic ring count, this series demonstrated improved solubility and permeability. However, plasma instability and fast metabolism limited its potential for in vivo studies. Efforts have been made to address these problems, which led to the discovery of compound (?)-11 with improved stability, CYP inhibition, and good activity/selectivity for further optimization.

PHARMACEUTICAL COMPOSITION HAVING PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT

[Problem] A pharmaceutical composition for treating FGFR4-related cancer, FGF 19-related cancer, or FGF19 gene amplification-positive liver cancer is provided. [Means for Solution] The present inventors have investigated a compound having an inhibitory ac